Startup · $37m raised · Healthcare
biotech startup
Newcastle, NSW
Every investor coverage indicates participated in a round ImmVirX raised.
| Investor | Rounds | Invested |
|---|---|---|
| Acorn Capital | Seed | - |
| One Ventures | undisclosed | - |
Companies ImmVirX acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming ImmVirX. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Techboard's June 2023 roundup of Australian startup funding, led by Pet Circle's $75m Series D, lists raises by Stacked Farm, Lyka, In1Bank, Splend, ImmVirX, Midnight Health, Sicona and Nutromics, and teases its FY23 review.
A quarterly Cut Through Venture survey reports Australian startups raised $810 million across 90 deals in Q2 2023, listing the largest rounds and noting improved investor sentiment despite a sluggish first half.
Also SmartCompany
OneVentures' blog links to an Australian Financial Review report saying biotech ImmVirX has secured a raise at a $75 million valuation; the post itself gives no amount, investors, or dates.
Also SmartCompany·Techboard
Weekly roundup covering six startup raises: ImmVirX, Nutromics, Nuheara, Autism 360, Cogo and Gather, plus Nutromics' 30X30 selection, a board appointment and Viralytics' earlier sale to Merck.